Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).

• Authors: ŽÁČKOVÁ Daniela; FABER Edgar; STEJSKAL L.; KARAS M.; BĚLOHLÁVKOVÁ P.; KLAMOVÁ H.; ČERNÁ O.; CMUNT Eduard; ČIČÁTKOVÁ Petra; SEMERÁD Lukáš; HORŇÁK Tomáš; KVETKOVÁ Anežka; PROCHÁZKOVÁ Jiřina; RYCHLÍČKOVÁ Jitka; ŠTĚPÁNOVÁ Radka; SVOBODNÍK Adam; MACHOVÁ POLÁKOVÁ Kateřina; JEŽÍŠKOVÁ Ivana; JURČEK Tomáš; BORSKÝ Marek; WIEWIORKA Ondřej; MAYER Jiří
• Year of publication: 2021
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF) - conference abstract from 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021.

Related projects

• Český národní uzel Evropské sítě infrastruktur klinického výzkumu (CZECRIN)